In August 2025, the first generic liraglutide for weight loss received full FDA approval and coverage for brand-name liraglutide dropped by nearly 90% following that approval
A multidisciplinary advisory from major nutrition, lifestyle medicine, obesity medicine, and obesity research organizations recommends screening dietary intake, medical conditions, strength, function, physical activity, and other lifestyle factors when initiating GLP-1 therapy
To distinguish between cognitive benefits derived from improved glycemic control versus direct neuroprotective mechanisms, we employ a comparative approach by including dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, as a reference treatment
Additionally, individuals with a history of yo-yo dieting, where weight is repeatedly lost and regained, may find weight loss injections helpful in maintaining more consistent results
Mechanism of Action: Acts on the pituitary and hypothalamus to release growth hormone